OpenNashEarnings

Health Insurance · NYSE: CNC

Centene earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 5 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Centene's Medicare Advantage turnaround reached break-even a year early, even as it narrows its 2027 MA footprint and prepares for Medicaid work requirements.

Centene's Medicare business was the standout this quarter. Medicare Advantage is now on track for break-even in 2026, a year ahead of plan, and standalone Part D performed well on disciplined bidding and scale. Marketplace pricing and moderating costs in its higher-acuity silver tier held up, while Medicaid stayed on its expected path as states trimmed rolls ahead of work requirements. Centene also decided to exit the Health Net commercial group business, largely in California.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$50.6B+1.9% y/yQ3 2026
Q4 2024: $40.8B (worked out from the annual figure)Q4 ’24$40.8BQ1 2025: $46.6BQ1 ’25$46.6BQ2 2025: $48.7BQ2 ’25$48.7BQ3 2025: $49.7BQ3 ’25$49.7BQ4 2025: $49.7B (worked out from the annual figure)Q4 ’25$49.7BQ1 2026: $49.9BQ1 ’26$49.9BQ2 2026: $53.6BQ2 ’26$53.6BQ3 2026: $50.6BQ3 ’26$50.6B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$40.8B *
Q1 2025$46.6B
Q2 2025$48.7B
Q3 2025$49.7B
Q4 2025$49.7B *
Q1 2026$49.9B
Q2 2026$53.6B
Q3 2026$50.6B
Diluted EPS (GAAP)-$0.14+99.0% y/yQ3 2026
Q1 2025: $2.63Q1 ’25$2.63Q2 2025: -$0.51Q2 ’25-$0.51Q3 2025: -$13.50Q3 ’25-$13.50Q1 2026: $3.11Q1 ’26$3.11Q2 2026: $2.19Q2 ’26$2.19Q3 2026: -$0.14Q3 ’26-$0.14
Data
Q1 2025$2.63
Q2 2025-$0.51
Q3 2025-$13.50
Q1 2026$3.11
Q2 2026$2.19
Q3 2026-$0.14

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin-0.6%+13.4 pts y/yQ3 2026
Q4 2024: 0.4%Q4 ’240.4%Q1 2025: 3.3%Q1 ’253.3%Q2 2025: -0.9%Q2 ’25-0.9%Q3 2025: -14.0%Q3 ’25-14.0%Q4 2025: -3.5%Q4 ’25-3.5%Q1 2026: 3.7%Q1 ’263.7%Q2 2026: 2.2%Q2 ’262.2%Q3 2026: -0.6%Q3 ’26-0.6%
Data
Q4 20240.4%
Q1 20253.3%
Q2 2025-0.9%
Q3 2025-14.0%
Q4 2025-3.5%
Q1 20263.7%
Q2 20262.2%
Q3 2026-0.6%
Free cash flow-$3.9BQ3 2026
Q4 2024: -$741.0MQ4 ’24-$741.0MQ1 2025: $1.4BQ1 ’25$1.4BQ2 2025: $1.6BQ2 ’25$1.6BQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $224.0MQ4 ’25$224.0MQ1 2026: $4.2BQ1 ’26$4.2BQ2 2026: $3.4BQ2 ’26$3.4BQ3 2026: -$3.9BQ3 ’26-$3.9B
Data
Q4 2024-$741.0M
Q1 2025$1.4B
Q2 2025$1.6B
Q3 2025$1.1B
Q4 2025$224.0M
Q1 2026$4.2B
Q2 2026$3.4B
Q3 2026-$3.9B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$40.8Bd$46.6B$48.7B$49.7B$49.7Bd$49.9B$53.6B$50.6B
Gross margin9.3%11.3%6.2%6.7%5.1%11.3%8.6%6.5%
Operating income$175.0Md$1.5B-$458.0M-$7.0B-$1.7Bd$1.9B$1.2B-$307.0M
Operating margin0.4%3.3%-0.9%-14.0%-3.5%3.7%2.2%-0.6%
Net income$283.0Md$1.3B-$253.0M-$6.6B-$1.1Bd$1.5B$1.1B-$71.0M
Diluted EPS—$2.63-$0.51-$13.50—$3.11$2.19-$0.14
Operating cash flow-$587.0Md$1.5B$1.8Bd$1.4Bd$437.0Md$4.4B$3.6Bd-$3.7B
Capital expenditure$154.0Md$135.0M$208.0Md$211.0Md$213.0Md$200.0M$174.0Md$194.0Md
Free cash flow-$741.0M$1.4B$1.6B$1.1B$224.0M$4.2B$3.4B-$3.9B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings